Merck & Co.

United Statesmerck.com

Its roles Owner Operator

projects tracked
5
active
2
countries
2
plants
7

Merck & Co., Inc. is a prominent American pharmaceutical company that specializes in the development and production of medicines, vaccines, and biologic products. Headquartered in the United States, it conducts extensive research and manufacturing activities across multiple states.

Read more

The company operates key facilities such as the Wilmington Merck Biologics site, the Durham Merck Vaccines plant, the Elkton Merck Pharmaceuticals and Vaccines location, the West Point Merck Vaccines and Biologics center, and the Riverside Merck Cherokee API facility. These sites support its involvement in centers of excellence for pharmaceutical manufacturing and expansions in vaccine production.

As a major player in the industry, Merck focuses on therapeutic areas including oncology, infectious diseases, and cardiovascular health. It is a publicly traded entity listed on major stock exchanges and maintains an independent structure separate from other entities with similar names.

Merck's contributions to the pharmaceutical sector include the production of innovative therapies that address global health needs, with operations primarily based in the US but extending internationally through its network.

Also known as MSD, Merck Sharp & Dohme, Merck Animal Health, MSD Animal Health, Merck Research Laboratories and 1 more.

Projects Merck is involved in

chemXplore tracks 5 projects involving Merck, of which 2 are active.

  1. none Announced / Concept
  2. none FEED / Pre-FID
  3. none FID / Sanctioned
  4. 2 projects Under Construction
  5. none Commissioning & Start-up

Besides these 2, the record holds 3 completed projects.

Active projects

Closest to start-up first.

The 3 that are completed, on hold or cancelled are in the record. See all 5 in chemXplore

What moved recently

  • 14 October 2026 Merck ADVANCE bioanalytical research facility, West Point · Operational / Completed · United States

Merck in chemical industry news

13 November 2026
Merck gets positive EU CHMP opinion for belzutifan–lenvatinib in advanced ccRCC

A European Commission decision is expected within two months. Phase 3 data showed a 26% lower risk of progression or death versus cabozantinib.

9 November 2026
Merck reports positive Phase 2b efinopegdutide data in MASH with F2–F3 fibrosis

Efinopegdutide achieved higher rates of MASH resolution and meaningful fibrosis improvement versus placebo at 52 weeks, with a safety profile broadly similar to semaglutide.

3 November 2026
Merck launches Phase 3 ENHANCE-3 trial of OHTUVAYRE (ensifentrine) to prevent COPD exacerbations

Randomized Phase 3 will enroll ~2,136 adults on standard COPD therapy to test whether add-on ensifentrine reduces annualized moderate/severe exacerbation rate over 52 weeks.

26 October 2026
Merck’s sacituzumab tirumotecan improves survival vs chemotherapy in advanced/recurrent endometrial cancer

Phase 3 TroFuse‑005 showed a 32% lower risk of death and 41% lower risk of progression or death, with a PDUFA target date of June 15, 2027.

26 October 2026
Merck: KEYTRUDA monotherapy lowers progression or death risk 43% in dMMR advanced or recurrent endometrial cancer

Phase 3 KEYNOTE‑C93: pembrolizumab alone extended median PFS to 38.2 vs 8.4 months versus platinum doublet; results presented at ESMO and published in The Lancet.

25 October 2026
Lilly's olomorasib shows durable first-line activity in KRAS G12C NSCLC

Durable PFS and DOR not reached with immunotherapy combo; chemoimmunotherapy combo showed 62% ORR and 14.5‑month median DOR in first-line KRAS G12C NSCLC.

22 October 2026
Merck and Moderna present Phase 3 INTerpath‑001: intismeran + KEYTRUDA reduces recurrence in resected stage IIB–IV melanoma

Intismeran plus pembrolizumab cut risk of recurrence or death 42% overall and 58% after six months; distant‑metastasis‑free survival also improved; safety profile consistent.

21 October 2026
Merck’s KEYTRUDA plus Padcev approved by European Commission for perioperative treatment of resectable MIBC

EU clears first PD‑1 inhibitor plus ADC regimen for resectable muscle‑invasive bladder cancer regardless of cisplatin eligibility; phase 3 showed EFS HR 0.53 and OS HR 0.65.

Where its projects are

active all projects

Partners on its projects